Nivolumab

Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma

David Bond, MDmonoclonal_antibodyPhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 95/ 100

Competitive context

6 Active assets in the Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide David Bond, MD	Phase 2	CCC
PREDNISONE TABLETS David Bond, MD	Phase 2	CCC
Inno-206 David Bond, MD	Phase 2	CCC
ETOPOSIDE David Bond, MD	Phase 2	CCC
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER David Bond, MD	Phase 2	CCC
VINCRISTINE SULFATE David Bond, MD	Phase 2	CCC